Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Qing Xia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5509-6981; OpenAlex author ID A5100673498. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers

Papers 7

  1. The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03644-2↗
  2. Correction to: The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03739-w↗
  3. Pancreatic STAT5 activation promotes Kras G12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332225↗
  4. Relationship between the expression of PD-L1 and 18F-FDG uptake in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-023-02297-9↗
  5. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02133-5↗
  6. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  7. The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients. Last author DOI 10.7150/jca.38981↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengbai Xue · 2 shared papers, 2024 · strength 0.40
  2. Yanling Wang · 2 shared papers, 2024 · strength 0.40
  3. Wenxin Lu · 2 shared papers, 2024 · strength 0.40
  4. Liwei Wang · 2 shared papers, 2024 · strength 0.40
  5. Jiajin Li · 2 shared papers, 2022–2023 · strength 0.32
  6. Yu Wang · 1 shared paper, 2024 · strength 0.20
  7. Zhihao Wu · 1 shared paper, 2024 · strength 0.18
  8. Xiangjun Meng · 1 shared paper, 2024 · strength 0.18
  9. Jun Wang · 1 shared paper, 2024 · strength 0.18
  10. Wenquan Wang · 1 shared paper, 2024 · strength 0.18
  11. Liang Liu · 1 shared paper, 2024 · strength 0.18
  12. Yuli Lin · 1 shared paper, 2024 · strength 0.18
  13. Xuguang Yang · 1 shared paper, 2024 · strength 0.18
  14. Jianjun Liu · 1 shared paper, 2023 · strength 0.17
  15. Ruohua Chen · 1 shared paper, 2023 · strength 0.17
  16. Yun Chen · 1 shared paper, 2022 · strength 0.15
  17. Liwei Wang · 1 shared paper, 2022 · strength 0.15
  18. Hai Hu · 1 shared paper, 2020 · strength 0.12
  19. Feng Jiao · 1 shared paper, 2021 · strength 0.10
  20. Xiaofei Zhang · 1 shared paper, 2021 · strength 0.10
  21. Tiebo Mao · 1 shared paper, 2021 · strength 0.10
  22. Liwei Wang · 1 shared paper, 2021 · strength 0.10
  23. Yiyi Liang · 1 shared paper, 2021 · strength 0.10
  24. Jiong Hu · 1 shared paper, 2021 · strength 0.10
  25. Yongwei Sun · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.